|
Dr. Gilad S. Gordon received an AB in Biochemistry from Harvard College in 1979, an MD from the HST program at Harvard Medical School and MIT in 1983, and an MBA from the University of Washington in 1988. He completed an internship and residency in Internal Medicine at the University of Colorado Health Sciences Center in 1986 and was a Senior Fellow in the Robert Wood Johnson Clinical Scholars Program at the University of Washington from 1986 to 1988. He has held academic medicine appointments in the Department of Medicine at the University of Indiana Medical School from 1988 to 1992 and is currently a Clinical Assistant Professor of Medicine at the University of Colorado Health Sciences Center.
Dr. Gordon�s career began at the Eli Lilly Company where he developed new methodologies for undertaking cost-effectiveness and quality of life research during clinical trials and was also involved in the development of various new drugs for cancer, infectious disease, and mental disease. He then moved to Colorado to work at Synergen, a bio-technology company developing drugs for sepsis and inflammation. He then spent four years working with clinical information systems and medical software designing and utilizing the systems to better understand and improve health care provision. Since 1998, Dr. Gordon has been focusing his work on the clinical development of new chemical entities and was most recently Vice President of Medical Affairs for FeRx, Inc. Over the past 3 years, Dr. Gordon has been serving as a consultant to the pharmaceutical and biotechnology industry helping small to medium sized organizations and universities design clinical programs, obtain funding for the programs, manage the clinical programs, and gain regulatory approval for their new drugs. His major focus has been in oncology concentrating on small molecules as targeted therapeutics.
Dr. Gordon is the Acting Chief Medical Officer for Kinex Pharmaceuticals. | 